Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
A list of letters sent to healthcare professionals in February 2010, to inform of new safety information and advice.
| Date issued | Product | Safety information |
|---|---|---|
| 4 February 2010 | Rapamune (sirolimus) (782Kb) |
Caution needed over use of different immunoassays for therapeutic drug monitoring. |
| 8 February 2010 | Protopic (topical tacrolimus) (981Kb) |
Reminder on recommended monitoring with maintenance treatment. |
| 12 February 2010 | Advagraf, Prograf and Modigraf (oral tacrolimus) (90Kb) |
Reminder on risk of medication errors with oral tacrolimus products. |
| 17 February 2010 | Tysabri (natalizumab) (68Kb) |
Updated information on risk of progressive multifocal leukoencephalopathy. |
| 17 February 2010 | Fabrazyme (agalsidase beta) (154Kb) |
Period of reduced supply will be extended until June 2010. |
| 17 February 2010 | Cerezyme (imiglucerase) (155Kb) |
A ‘reduced demand’ shipping period will be implemented from 22 February to 16 April 2010 to cope with product shortages. |
